Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + melphalan + prednisone in relapsed/refractory multiple myeloma (Phase II)
2008-004165-26Phase 2Terminated
- Sponsor
- Fondazione EMN Italy
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Therapeutic benefit and safety of dasatinib + melphalan + prednisone. Started Sep 2008; status: terminated.
02
Drugs
dasatinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-004165-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004165-26.